[email protected]

国际临床研究杂志

International Journal of Clinical Research

您当前位置:首页 > 精选文章

International Journal of Clinical Research. 2022; 6: (1) ; 10.12208/j.ijcr.20220028 .

A case of recurrence of hilar cholangiocarcinoma treated with PD-1 antibody
PD-1抗体治疗肝门部胆管癌复发一例

作者: 谭元灿, 张治清 *, 杨洪, 郭鹏, 别平

重庆医科大学附属第三医院肝胆胰外科 重庆

*通讯作者: 张治清,单位:重庆医科大学附属第三医院肝胆胰外科 重庆;

收录截图(CNKI-Scholar)

引用本文: 谭元灿, 张治清, 杨洪, 郭鹏, 别平 PD-1抗体治疗肝门部胆管癌复发一例[J]. 国际临床研究杂志, 2022; 6: (1) : 163-166.
Published: 2022/3/9 17:25:30

摘要

患者男性,因肝门部胆管癌于2019年3月22日在我院行右半肝切除+胆肠吻合术。术后患者规律化疗9次因不能耐受停止化疗,术后6个月复查显示肝内多发转移灶。因患者不能耐受化疗,遂予以PD-1抗体(信迪利单抗注射液)治疗,4周期后复查显示肝内病灶明显减少,胆肠吻合口占位消失、胆红素及肝功能几乎恢复正常。

关键词: 胆管恶性肿瘤;黄疸;PD-1抗体

Abstract

The male patient underwent right hepatectomy + cholangioenterostomy in our hospital on March 22, 2019 due to hilar cholangiocarcinoma. The patient stopped chemotherapy for 9 times of regular chemotherapy after surgery because of intolerance, and the follow-up 6 months after surgery showed multiple intrahepatic metastases. Because the patient could not tolerate chemotherapy, he was treated with PD-1 antibody (sintilimab injection). After 4 cycles, the re-examination showed that the intrahepatic lesions were significantly reduced, the biliary-enteric anastomotic stoma disappeared, and the bilirubin and liver function were almost the same. Back to normal.

Key words: Malignant Tumor of Bile Duct; Jaundice; PD-1 Antibody

参考文献 References

[1] Benson AB, D'Angelica MI, Abbott DE, et al. Guidelines Insights: Hepatobiliary Cancers, Version 2.2019. J Natl Compr Canc Netw[J]. 2019;17(4):302-310. doi:10.6004/jnccn.2019.0019

[2] 隋明昊,卢实春.PD-1抗体治疗肝内胆管细胞癌术后复发一例[J].中华肝胆外科杂志,2019,25(2):144-146.

[3] Chen WX, Li GX, Hu ZN, etal. Significant response to anti-PD-1 based immunotherapy plus lenvatinib for recurrent intrahepatic cholangiocarcinoma with bone metastasis: A case report and literature review. Medicine (Baltimore) [J]. 2019;98(45):e17832.doi:10.1097/MD.0000000000017832

[4] 何珊,黄银久,闵静婷等.肝内胆管细胞癌组织中 PD - L1 表达及与临床病理特征的关系.现代肿瘤医学,2020.28(15):2663-2666.

[5] Ma K, Wei X, Dong D, Wu, et al. PD-L1 and PD-1 expression correlate with prognosis in extrahepatic cholangiocarcinoma. Oncol Lett. 2017;14(1):250-256. doi:10.3892/ol.2017.6105。

[6] Mody K, Starr J, Saul M, et al. Patterns and genomic correlates of PD-L1 expression in patients with biliary tract cancers. J Gastrointest Oncol. 2019;10(6):1099-1109.doi:10.21037/jgo.2019.08.08

[7] 王毅欣,胡宗涛,张永康等.PD-1治疗晚期原发性肝癌患者的安全性及临床疗效观察[J].肿瘤防治研究,2020.47(4):298-302.